Research progress of anti-leucine-rich glioma-inactivated 1 protein antibody-associated encephalitis
10.3760/cma.j.cn431274-20240924-01462
- VernacularTitle:抗富亮氨酸胶质瘤失活1蛋白抗体相关脑炎的研究进展
- Author:
Kaiyue YAN
1
;
Shanshan JIA
;
Xia LI
;
Dong WANG
;
Zhijing WANG
;
Yan WANG
;
Liang LIU
;
Bei LI
;
Lili LIANG
;
Yan WU
Author Information
1. 西安市儿童医院神经内科，西安 710000
- Publication Type:Journal Article
- Keywords:
Leucine rich glioma inactivated 1 antibody;
Autoimmune encephalitis
- From:
Journal of Chinese Physician
2025;27(11):1747-1752
- CountryChina
- Language:Chinese
-
Abstract:
Anti-leucine-rich glioma-inactivated 1 protein (LGI1) antibody-associated encephalitis is an autoimmune encephalitis mediated by LGI1 antibodies, which can occur in both adults and children. Its common clinical manifestations include epileptic seizures, cognitive and psychiatric disorders; rare symptoms include sleep disorders and autonomic disorders; and its characteristic manifestations are faciobrachial dystonic seizures and refractory hyponatremia. Since anti-LGI1 antibody-associated encephalitis is relatively rare in clinical practice, this article reviews the disease in terms of etiology and pathogenesis, clinical manifestations, auxiliary examinations, diagnosis and differential diagnosis, treatment, recurrence and prognosis. It aims to improve clinicians′ understanding of this disease, provide references for its early diagnosis and treatment, and thereby improve patients′ prognosis.
